HC Wainwright reaffirms "Buy" rating on Hookipa Pharma (HOOK) at $6.50, while RBC lowers price target to $5.00 and maintains "outperform".
HC Wainwright reaffirmed its "Buy" rating on Hookipa Pharma (HOOK) with a $6.50 price target, while Royal Bank of Canada reduced its price target to $5.00 and maintained an "outperform" rating. The clinical-stage biopharmaceutical firm, HOOKIPA Pharma, develops immunotherapeutics for infectious diseases and cancers, with its lead infectious disease product candidate, HB-101, in a Phase 2 clinical trial. As of Q4 2021, 63.88% of HOOKIPA Pharma's stock is owned by hedge funds and other institutional investors.
March 29, 2024
4 Articles